Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives-Reference-Cited by-同舟云学术

Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives

Published:2017-08-24 Issue:3 Volume:166 Page:951-963
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Diaby Vakaramoko^ORCID,Ali Askal Ayalew,Williams Krystal J.,Ezendu Kyrian,Soto-Perez-de-Celis Enrique,Chavarri-Guerra Yanin,de Lima Lopes Gilberto

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-017-4473-4/fulltext.html

Reference48 articles.

1. Soto-Perez-de-Celis E, Chavarri-Guerra Y (2016) National and regional breast cancer incidence and mortality trends in Mexico 2001–2011: analysis of a population-based database. Cancer Epidemiol 41:24–33

2. Villarreal-Garza C, Mohar A, Bargallo-Rocha JE et al (2017) Molecular subtypes and prognosis in young Mexican women with breast cancer. Clin Breast Cancer 17:e95–e102

3. Reynoso-Noverón N, Villarreal-Garza C, Soto-Perez-de-Celis E et al (2017) Clinical and epidemiological profile of breast cancer in Mexico: results of the Seguro Popular. JGO 2016:007377

4. Perez-Rodriguez G (2015) Prevalence of breast cancer sub-types by immunohistochemistry in patients in the Regional General Hospital 72, Instituto Mexicano del Seguro Social. Cirugía y Cirujanos (English Edition) 83:193–198

5. Villarreal-Garza C, Bargallo-Rocha JE, Soto-Perez-de-Celis E et al (2016) Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 157:385–394

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Evaluation of Neoadjuvant Treatment Strategies for HER2 Positive Breast Cancer: A Systematic Review;International Journal of Cancer Management;2023-12-20

2. Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer;Journal of Clinical Oncology;2023-01-01

3. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer;Frontiers in Pharmacology;2022-09-09

4. Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models;PharmacoEconomics;2021-11-29

5. Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China;Annals of Palliative Medicine;2021-11